<DOC>
	<DOCNO>NCT02367820</DOCNO>
	<brief_summary>The purpose 52-week open label study determine safety new opioid molecule , NKTR-181 , patient moderate severe chronic low back pain chronic non-cancer pain .</brief_summary>
	<brief_title>Long-Term Safety Tolerability Study NKTR-181 Subjects With Chronic Low Back Pain Chronic Non-Cancer Pain</brief_title>
	<detailed_description>This open-label safety tolerability study approximately 600 subject receive NKTR-181 52 week . Subjects may include newly enrol subject subject recently complete SUMMIT-07 SUMMIT-12 study . This study also investigate pharmacokinetics NKTR-181 patient chronic low back pain chronic non-cancer pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Male nonpregnant , nonnursing female age 18 75 year old Clinical diagnosis moderate severe , chronic low back noncancer pain least three month Not experience adequate pain relief fail previous treatment nonopioid analgesic Opioid analgesia necessary Currently take 60 mg morphine sulfate equivalent per day opioid analgesic least 7 day prior entry Females child bear potential must use highly effective form birth control . All subject must agree use doublebarrier contraception participation study least 2 month last dose study drug . Willing able provide inform consent History hypersensitivity , intolerance , allergy opioids Surgical procedure last 4 week plan undergo surgical procedure study period Untreated moderate severe sleep apnea Chronic migraine primary pain condition Cancer relate pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>